CARE-HF LTFU: CArdiac REsynchronization in Heart Failure Long-Term Follow-up
Recruitment status was Active, not recruiting
The CARE-HF long-term follow-up trial evaluates the effects of cardiac resynchronization (CR) therapy on the mortality of patients from the CARE-HF program for an additional 4 year follow-up. Investigators are free to choose whatever available treatment they believe is in the patient's best interest.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||CARE-HF LTFU: CArdiac REsynchronization in Heart Failure Long-Term Follow-up|
- All cause Mortality [ Time Frame: 4-year ] [ Designated as safety issue: No ]
Biospecimen Retention: None Retained
No biospecimens are retained
|Study Start Date:||September 2006|
|Estimated Study Completion Date:||July 2010|
|Estimated Primary Completion Date:||July 2010 (Final data collection date for primary outcome measure)|
In the CARE-HF study patients treated with standard medical treatment plus CRT were compared to patients treated with standard medical treatment.
Device: Medtronic CRT InSync® family devices
Implantation of CRT device and medical treatment according normal hospital routine.
Other Name: Resynchronisation system of the InSync® family
The CARE-HF study enrolled 813 patients from 82 centers in 12 European countries (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, and UK). All patients that were reported to be alive in May 2005 will be asked to participate.
|Hull Royal Infirmary - Academic Cardiology Unit|
|Cottingham, Kingston-Upon-Hull, United Kingdom, HU16 5JQ|
|Study Chair:||John Cleland, Professor||The University of Hull; Department of Cardiology; United Kingdom|